BR112014001441A2 - copolímeros em multi-blocos termoplásticos, de fase separada, semi-cristalinos, biodegradáveis para liberação controlada de compostos biologicamente ativos - Google Patents

copolímeros em multi-blocos termoplásticos, de fase separada, semi-cristalinos, biodegradáveis para liberação controlada de compostos biologicamente ativos

Info

Publication number
BR112014001441A2
BR112014001441A2 BR112014001441A BR112014001441A BR112014001441A2 BR 112014001441 A2 BR112014001441 A2 BR 112014001441A2 BR 112014001441 A BR112014001441 A BR 112014001441A BR 112014001441 A BR112014001441 A BR 112014001441A BR 112014001441 A2 BR112014001441 A2 BR 112014001441A2
Authority
BR
Brazil
Prior art keywords
crystalline
semi
biologically active
controlled release
active compounds
Prior art date
Application number
BR112014001441A
Other languages
English (en)
Inventor
Hiemstra Christine
Zuidema Johan
Steendam Rob
Adrianus Cornelius Flipsen Theodorus
Original Assignee
Innocore Tech B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innocore Tech B V filed Critical Innocore Tech B V
Publication of BR112014001441A2 publication Critical patent/BR112014001441A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • C08G63/668—Polyesters containing oxygen in the form of ether groups derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/672—Dicarboxylic acids and dihydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/002—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L101/00—Compositions of unspecified macromolecular compounds
    • C08L101/16—Compositions of unspecified macromolecular compounds the macromolecular compounds being biodegradable
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L87/00—Compositions of unspecified macromolecular compounds, obtained otherwise than by polymerisation reactions only involving unsaturated carbon-to-carbon bonds
    • C08L87/005—Block or graft polymers not provided for in groups C08L1/00 - C08L85/04
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/38—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing oxygen in addition to the ether group
    • C08G2650/42—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing oxygen in addition to the ether group containing orthoester groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
BR112014001441A 2011-07-22 2012-07-23 copolímeros em multi-blocos termoplásticos, de fase separada, semi-cristalinos, biodegradáveis para liberação controlada de compostos biologicamente ativos BR112014001441A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11174987 2011-07-22
PCT/NL2012/050529 WO2013015685A1 (en) 2011-07-22 2012-07-23 Biodegradable, semi-crystalline, phase separated, thermoplastic multi block copolymers for controlled release of biologically active compounds

Publications (1)

Publication Number Publication Date
BR112014001441A2 true BR112014001441A2 (pt) 2019-05-14

Family

ID=46704994

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014001441A BR112014001441A2 (pt) 2011-07-22 2012-07-23 copolímeros em multi-blocos termoplásticos, de fase separada, semi-cristalinos, biodegradáveis para liberação controlada de compostos biologicamente ativos

Country Status (18)

Country Link
US (2) US20140199385A1 (pt)
EP (1) EP2734573B1 (pt)
JP (2) JP6174023B2 (pt)
KR (1) KR101889586B1 (pt)
CN (1) CN103827177B (pt)
AU (1) AU2012287577B2 (pt)
BR (1) BR112014001441A2 (pt)
CA (1) CA2842514C (pt)
CL (1) CL2014000159A1 (pt)
CO (1) CO7020923A2 (pt)
ES (1) ES2899701T3 (pt)
IL (1) IL230606B (pt)
MX (1) MX362941B (pt)
MY (1) MY169349A (pt)
RU (2) RU2018125698A (pt)
UA (1) UA112192C2 (pt)
WO (1) WO2013015685A1 (pt)
ZA (1) ZA201400846B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018125698A (ru) * 2011-07-22 2019-03-13 Иннокор Текнолоджис Б.В. Биоразлагаемые полукристаллические термопластичные мультиблочные сополимеры с разделенными фазами для контролируемого высвобождения биологически активных соединений
RU2694901C2 (ru) * 2013-04-18 2019-07-18 Шаньдун Луе Фармасьютикал Ко., Лтд Фармацевтические композиции микросфер гозерелина с пролонгированным высвобождением
JO3394B1 (ar) 2014-07-04 2019-10-20 Osteo Pharma B V تركيبات ومنتجات للاستعمال في علاج كسور وعيوب العظام
CN105273153A (zh) * 2014-07-24 2016-01-27 允友成(宿迁)复合新材料有限公司 一种可降解生物基水性乳液及其制备方法
CN105273154A (zh) * 2014-07-24 2016-01-27 允友成(宿迁)复合新材料有限公司 一种可降解聚乳酸基水性乳液及其制备方法
WO2016025911A1 (en) * 2014-08-14 2016-02-18 Brown University Compositions for stabilizing and delivering proteins
US20170354519A1 (en) 2014-11-14 2017-12-14 University College Cork - National University Of Ireland, Cork Delivery of igf-1 in myocardial infarction
KR102009972B1 (ko) * 2015-11-25 2019-10-21 주식회사 엘지화학 양친성 고분자
KR102001614B1 (ko) * 2015-11-25 2019-07-18 주식회사 엘지화학 양친성 고분자
CN108410295B (zh) * 2015-12-22 2020-09-25 江门市蓬江区巨匠涂料化工有限公司 抗菌耐划伤漆
WO2017217813A1 (ko) * 2016-06-16 2017-12-21 주식회사 엘지화학 양친성 고분자
JP6887713B2 (ja) * 2016-06-16 2021-06-16 エルジー・ケム・リミテッド 両親媒性高分子
US11034786B2 (en) 2016-06-16 2021-06-15 Lg Chem, Ltd. Amphiphilic triblock polymer
CN110234336A (zh) 2017-01-31 2019-09-13 维鲁公司 用于促性腺激素释放激素(GnRH)拮抗剂的长效释放的组合物和方法
CN107376026B (zh) * 2017-07-15 2019-03-19 深圳市立心科学有限公司 可吸收的生物医用复合材料及其制备方法
KR20200060729A (ko) 2017-10-04 2020-06-01 패션 케미칼즈 게엠베하 운트 코. 카게 신규한 폴리락트산의 에스테르 및 이의 조성물
US20210002432A1 (en) * 2018-03-30 2021-01-07 Toray Industries, Inc. Biodegradable block copolymer
CN108387664B (zh) * 2018-07-03 2020-06-23 中国食品药品检定研究院 人血白蛋白分子大小分布超高效液相色谱测定方法
WO2020071912A1 (en) 2018-10-02 2020-04-09 Innocore Technologies B.V. Extended release formulations of human chorionic gonadotropin (hcg)
AU2020245092A1 (en) * 2019-03-28 2021-10-14 Pk Med Multicomponent thermoplastic product
US20210017329A1 (en) * 2019-07-19 2021-01-21 Evonik Operations Gmbh Multi-block shape memory bioresorbable polymers
WO2021066650A1 (en) 2019-10-01 2021-04-08 Innocore Technologies B.V. Biodegradable, phase separated, thermoplastic multi-block copolymer
WO2021067388A1 (en) 2019-10-01 2021-04-08 Allergan Sales, Llc Poly-dioxanone multi-block copolymer for ocular protein delivery
EP4051233A1 (en) 2019-11-01 2022-09-07 InnoCore Technologies Holding B.V. Dosage form for extended release of an antibody or large protein
EP4072607A4 (en) * 2019-12-12 2024-01-10 Massachusetts Eye and Ear Infirmary 3D PRINTING INKS THAT CAN BE MELT EXTRUDED
JP2023515407A (ja) * 2020-02-21 2023-04-13 ネイチャーワークス・エル・エル・シー 低分子量の非晶質グレードのポリ乳酸樹脂を含有する化粧用組成物
CA3179866A1 (en) * 2020-04-10 2021-10-14 Scienture, Inc. Long-acting apomorphine formulations and injectors for therapeutic delivery of the same
EP4138783A4 (en) 2020-04-22 2024-04-10 Scienture, Inc. LONG-ACTING BUPIVACAIN MICROSPHERE FORMULATIONS
CN111484635B (zh) * 2020-06-10 2023-09-12 杭州铭善生物科技有限公司 一种温敏性水凝胶材料的改性方法、改性温敏性水凝胶材料和生物3d打印墨水
CN112336689B (zh) * 2020-10-30 2022-06-28 浙江大学衢州研究院 一种结晶性嵌段共聚物胶束制备多重Pickering乳液的方法
WO2022159658A1 (en) * 2021-01-22 2022-07-28 University Of Connecticut Synthetic artificial stem cells (sasc)
CN114737276B (zh) * 2022-03-11 2023-02-07 北京朗净汇明生物科技有限公司 一种耐热抗水解型聚乳酸纤维及其制备方法
AU2023235001A1 (en) 2022-03-17 2024-10-17 InnoCore Technologies Holding B.V. Biodegradable thermoplastic poly(ortho ester) based multiblock copolymers

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4429080A (en) 1982-07-01 1984-01-31 American Cyanamid Company Synthetic copolymer surgical articles and method of manufacturing the same
US5066772A (en) 1987-12-17 1991-11-19 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5133739A (en) 1990-02-06 1992-07-28 Ethicon, Inc. Segmented copolymers of ε-caprolactone and glycolide
CN1037612C (zh) * 1992-07-20 1998-03-04 中国科学院化学研究所 热致形状可回复性多嵌段聚合物材料
US5236444A (en) 1992-10-27 1993-08-17 United States Surgical Corporation Absorbable polymers and surgical articles made therefrom
DK0678018T3 (da) * 1993-01-06 2003-04-28 Kinerton Ltd Ion molekylærkonjugater af bionedbrydelige polyestere og bioaktive polypeptider
US5403347A (en) 1993-05-27 1995-04-04 United States Surgical Corporation Absorbable block copolymers and surgical articles fabricated therefrom
US5711958A (en) 1996-07-11 1998-01-27 Life Medical Sciences, Inc. Methods for reducing or eliminating post-surgical adhesion formation
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6211249B1 (en) 1997-07-11 2001-04-03 Life Medical Sciences, Inc. Polyester polyether block copolymers
KR100382568B1 (ko) 1998-02-23 2003-05-09 메사츄세츠 인스티튜트 어브 테크놀로지 생물분해성 형상기억 중합체
US8158143B2 (en) 2000-07-14 2012-04-17 Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect
EP1382628A1 (en) * 2002-07-16 2004-01-21 Polyganics B.V. Biodegradable phase separated segmented/block co-polyesters
EP1555278A1 (en) * 2004-01-15 2005-07-20 Innocore Technologies B.V. Biodegradable multi-block co-polymers
US20090004243A1 (en) * 2007-06-29 2009-01-01 Pacetti Stephen D Biodegradable triblock copolymers for implantable devices
RU2018125698A (ru) * 2011-07-22 2019-03-13 Иннокор Текнолоджис Б.В. Биоразлагаемые полукристаллические термопластичные мультиблочные сополимеры с разделенными фазами для контролируемого высвобождения биологически активных соединений

Also Published As

Publication number Publication date
MX362941B (es) 2019-02-27
MY169349A (en) 2019-03-21
UA112192C2 (uk) 2016-08-10
JP2014521762A (ja) 2014-08-28
CL2014000159A1 (es) 2014-08-29
IL230606A0 (en) 2014-03-31
CN103827177A (zh) 2014-05-28
AU2012287577A1 (en) 2014-03-13
KR20140048296A (ko) 2014-04-23
RU2018125698A (ru) 2019-03-13
MX2014000891A (es) 2015-05-11
RU2014102900A (ru) 2015-08-27
CA2842514C (en) 2018-12-18
AU2012287577B2 (en) 2017-02-16
KR101889586B1 (ko) 2018-09-20
ZA201400846B (en) 2016-08-31
CN103827177B (zh) 2016-02-10
IL230606B (en) 2019-07-31
EP2734573A1 (en) 2014-05-28
ES2899701T3 (es) 2022-03-14
EP2734573B1 (en) 2021-09-08
JP6174023B2 (ja) 2017-08-02
JP6472836B2 (ja) 2019-02-20
NZ620392A (en) 2016-02-26
CO7020923A2 (es) 2014-08-11
US20140199385A1 (en) 2014-07-17
US20180085318A1 (en) 2018-03-29
WO2013015685A1 (en) 2013-01-31
RU2662818C2 (ru) 2018-07-31
CA2842514A1 (en) 2013-01-31
JP2017141477A (ja) 2017-08-17
US10300019B2 (en) 2019-05-28

Similar Documents

Publication Publication Date Title
BR112014001441A2 (pt) copolímeros em multi-blocos termoplásticos, de fase separada, semi-cristalinos, biodegradáveis para liberação controlada de compostos biologicamente ativos
CO6791604A2 (es) Compuesto para liberación controlada de agentes de tratamiento de pozos
BR112013021368A2 (pt) implante, especialmente para oclusão de abeurismas bifurcais
CO6940430A2 (es) Nuevos portadores recubiertos para la liberación controlada de agente activo
ES2626492T8 (es) Procedimiento para la expansión de células T
EP2714015A4 (en) SOLID DOSAGE FORMS WITH CONTROLLED RELEASE
BR112013002871A2 (pt) derivados de isoxazolina como agentes antiparasitários
DK2691079T3 (da) Bionedbrydelige sammensætninger, der er egnet til kontrolleret udløsning
BR112013028128A2 (pt) composição de polímero para dispositivos elétricos
FI20116138L (fi) Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen
BR112013002290A2 (pt) método para controlar estrutura de cadeia de copolímeros
BRPI1100018A2 (pt) metodo para polimeralização em fase de alfa- olefina
BR112013016491A2 (pt) método para tratamento de têxtil
ES2984717T3 (es) Formulaciones de péptidos de liberación controlada
CO6890111A2 (es) Derivados de isoxazolina como compuestos insecticidas
BR112013028282A2 (pt) composição de polímero para dispositivos elétricos
DE112012003251A5 (de) Ausrücksystem
CO6791617A2 (es) Combinaciones de compuestos activos
DK2536422T3 (da) Fremgangsmåder til behandling af diabetiske fodsår
BR112014000017A2 (pt) composição de polipropileno
BR112014015218A8 (pt) sistemas de afastadores cirúrgicos
DK2673096T3 (da) Fremgangsmåde til behandling af affaldsgenstande
CO6960544A2 (es) Preparación de liberación sostenida
CU24076B1 (es) Composición para el control de patógenos
CO6821942A2 (es) Combinaciones de compuestos activos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.1 NA RPI NO 2578 DE 02/06/2020 POR TER SIDO INDEVIDA.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements